Oral Anticoagulant Therapy and Endovascular Procedures.

Ann Vasc Surg

Department of Specialistic, Diagnostic and Experimental Medicine, Unit of Vascular Surgery, University of Bologna, Policlinico S. Orsola Malpighi, Bologna, Italy.

Published: May 2016

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.avsg.2016.01.006DOI Listing

Publication Analysis

Top Keywords

oral anticoagulant
4
anticoagulant therapy
4
therapy endovascular
4
endovascular procedures
4
oral
1
therapy
1
endovascular
1
procedures
1

Similar Publications

Atrial fibrillation (AF) and heart failure (HF) often accompany each other, as they share similar risk factors and pathophysiological mechanisms. AF in patients with HF is known to increase hospitalizations and worsen prognosis. A combination of AF and HF translates into high risks of thromboembolic complications, which renders anticoagulants an important aspect of therapy for these patients.

View Article and Find Full Text PDF

Background: Venous thromboembolism (VTE) is a common complication after hip arthroplasty. Here, we investigated the clinical efficacy and safety of prophylactic aspirin vs. conventional therapy in hip arthroplasty for femoral neck fracture.

View Article and Find Full Text PDF

Background: Delayed lead perforation is a rare complication of cardiac implantable electronic device (CIED). Clinical presentations range from completely asymptomatic to pericardial tamponade. Surgical lead extraction is recommended and transvenous lead extraction (TLE) with surgical backup is an alternative method.

View Article and Find Full Text PDF

Nowadays, direct oral anticoagulants (DOACs) represent the gold standard for venous thromboembolism (VTE) treatment and VTE secondary prophylaxis; nevertheless, the percentage of elderly patients in major trials and literature data about DOACs usage for VTE secondary prophylaxis in the elderly are scant. Our retrospective study tried to evaluate low-dose DOACs efficacy and safety for elderly VTE secondary prophylaxis in a real-life setting. A cohort of 73 patients (≥ 75 years) considered at high risk of VTE recurrence was treated with apixaban 2.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!